fostamatinib
chemical compound
≈ 4 min read
Names in other languages
- Englishfostamatinib
- FrançaisFostamatinib
- nnfostamatinib
- Polskifostamatinib
- РусскийФостаматиниб
- shFostamatinib
- СрпскиFostamatinib
- Українськафостаматиніб
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Fostamatinib, sold under the brand names Tavalisse and Tavlesse, is a tyrosine kinase inhibitor medication for the treatment of chronic immune thrombocytopenia (ITP). The drug is administered by mouth. Fostamatinib blocks the activity of the enzyme spleen tyrosine kinase (SYK).
This enzyme is involved in stimulating parts of the immune system. By blocking SYK's activity, fostamatinib reduces the immune system's destruction of platelets, so allowing the platelet count to rise, which reduces the likelihood of excessive bleeding.
The most commonly reported side effects are diarrhea, high blood pressure, nausea, respiratory infection, dizziness, increased liver enzymes, rash, abdominal pain, fatigue, chest pain and decreased white blood cell count. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Medical uses
Fostamatinib is a drug used to treat adults with low platelet count due to chronic immune thrombocytopenia (ITP) when a prior treatment for ITP has not worked well enough. Chronic immune thrombocytopenia is an autoimmune bleeding disorder where the blood doesn't clot as it should because of a low platelet count.
Clinical trials
Fostamatinib has been in clinical trials for rheumatoid arthritis, autoimmune thrombocytopenia, autoimmune hemolytic anemia, IgA nephropathy, and lymphoma. The drug is currently being used in a Phase 1 trial to test the safety of the combination of the study drugs fostamatinib and paclitaxel for patients with ovarian cancer.
The investigation of fostamatinib began with studies involving the treatment of mouse models with cytopenia. Mice were used to measure the effectiveness of R788, a small molecule prodrug of the biologically active R406, a Syk inhibitor.
In animal models, treatment with R406/R788 was shown to be safe and effective in reducing inflammation and joint damage in immune-mediated rheumatoid arthritis. The models responded favorably to treatment so the study progressed to Phase 2 trials involving humans.
Human studies have shown that R788 has good oral bioavailability, biologic activity, is well tolerated, and does not exhibit collagen or ADP-induced platelet aggregation. In NCT00706342, 16 adults with chronic ITP were entered into an open-label, single-arm cohort dose-escalation trials beginning with 75 mg and rising to 175 mg twice a day.
The dose was increased until a persistent response was evident, toxicity was reached, or 175 mg twice a day was met. 8 patients achieved persistent responses with platelet counts greater than 50,000 mm 3 /L on more than 67% of their visits. 3 of these patients had not persistently responded to thrombopoietic agents.
4 others had nonsustained responses. Mean peak platelet count exceeded 100,000 mm 3 /L in these 12 patients. Toxicity was evidenced primarily in GI-related side effects, notable diarrhea, urgency, and vomiting.
2 patients developed transaminitis. Fostamatinib as a treatment for severe COVID19 complications has finished a Phase 2 trial, and is entering a Phase 3 trial.
Synthesis
A large scale synthetic route to fostamatinib has been reported by Rigel Pharmaceuticals and is outlined below: The halogenation of 5-fluorouracil [51-21-8] (1) with phosphoryl chloride at high temperature gave 2,4-dichloro-5-fluoropyrimidine [2927-71-1] (2). Regioselective reaction with one equivalent of 6-amino-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one [1002726-62-6] (3) gave pyrimidine [575484-83-2] (4).
Substituting the remaining chlorine with 3,4,5-trimethoxyaniline [24313-88-0] (5) gave Tamatinib [841290-80-0] (6). Alkylation with Di-tert-butyl (chloromethyl) phosphate [229625-50-7] (7) under basic conditions gave [901119-38-8] (8). {The phosphate was prepared in a single step from chloromethyl sulfurochloridate and potassium di-t-butyl phosphate.}.
Heating with acetic acid facilitated t-butyl cleavage and precipitation of phosphonic acid (9) as an acetic acid solvate.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370865641 under CC BY-SA 4.0; modifications have been made.